These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7155241)

  • 41. [ABO blood groups in patients with nephropathies].
    Voigtmann B; Burchardt U
    Z Gesamte Inn Med; 1991 Apr; 46(5):156-9. PubMed ID: 2068845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [CAT in hepatorenal polycystosis in the adult].
    Gironella Coll J; Martínez Marsal E; Peyri Rey E
    Arch Esp Urol; 1988; 41(9):877-9. PubMed ID: 3228315
    [No Abstract]   [Full Text] [Related]  

  • 43. Case study. Dirty blood.
    Hastings Cent Rep; 2009; 39(5):13. PubMed ID: 19806771
    [No Abstract]   [Full Text] [Related]  

  • 44. Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
    Braun C; Kleemann T; Hilgenfeldt U; Riester U; Rohmeiss P; van der Woude FJ
    Kidney Int; 2002 Jun; 61(6):2149-56. PubMed ID: 12028455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Juvenile nephronophthisis and renal medullary cystic disease.
    Gardner KD
    Perspect Nephrol Hypertens; 1976; 4():173-85. PubMed ID: 1264565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic treatment with tempol does not significantly ameliorate renal tissue hypoxia or disease progression in a rodent model of polycystic kidney disease.
    Ding A; Kalaignanasundaram P; Ricardo SD; Abdelkader A; Witting PK; Broughton BR; Kim HB; Wyse BF; Phillips JK; Evans RG
    Clin Exp Pharmacol Physiol; 2012 Nov; 39(11):917-29. PubMed ID: 23006058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of association of ACE/angiotensinogen genotype with renal function in autosomal dominant polycystic kidney disease.
    Saggar-Malik AK; Afzal AR; Swissman JS; Bland M; Sagnella GA; Eastwood JB; MacGregor GA; Jeffery S
    Genet Test; 2000; 4(3):299-303. PubMed ID: 11142763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
    Spichtig D; Zhang H; Mohebbi N; Pavik I; Petzold K; Stange G; Saleh L; Edenhofer I; Segerer S; Biber J; Jaeger P; Serra AL; Wagner CA
    Kidney Int; 2014 Jun; 85(6):1340-50. PubMed ID: 24402093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A mechanistic approach to inherited polycystic kidney disease.
    Bissler JJ; Dixon BP
    Pediatr Nephrol; 2005 May; 20(5):558-66. PubMed ID: 15719257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time for reflection predicts the progression of renal dysfunction in patients with nondiabetic chronic kidney disease.
    Takenaka T; Mimura T; Kikuta T; Kato N; Inoue T; Kanno Y; Ohno Y; Kobayashi T; Miyawaki Y; Suzuki H
    Clin Exp Hypertens; 2009 May; 31(3):220-30. PubMed ID: 19387898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autosomal recessive polycystic kidney disease: improvement of renal function.
    Bosch BM; Plank C; Rascher W; Dötsch J
    Eur J Pediatr; 2003 Jun; 162(6):438-9. PubMed ID: 12756563
    [No Abstract]   [Full Text] [Related]  

  • 52. [Relationship between plasma cloxacillin clearance and endogenous creatinine clearance].
    Sieniawska M; Wróblewska-Kałuzewska M; Korniszewska J; Wierzbowska-Lange B; Białasik D; Karczeńska J; Wierzba K
    Pediatr Pol; 1979 Feb; 54(2):125-32. PubMed ID: 432009
    [No Abstract]   [Full Text] [Related]  

  • 53. Nerve conduction velocity in relationship to the severity of renal disease.
    Blagg CR; Kemble F; Taverner D
    Nephron; 1968; 5(4):290-9. PubMed ID: 5670180
    [No Abstract]   [Full Text] [Related]  

  • 54. Chronic caffeine consumption exacerbates hypertension in rats with polycystic kidney disease.
    Tanner GA; Tanner JA
    Am J Kidney Dis; 2001 Nov; 38(5):1089-95. PubMed ID: 11684564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Calcium, cyclic AMP, and MAP kinases: dysregulation in polycystic kidney disease.
    Cowley BD
    Kidney Int; 2008 Feb; 73(3):251-3. PubMed ID: 18195694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. mTOR is out of control in polycystic kidney disease.
    Mostov KE
    Proc Natl Acad Sci U S A; 2006 Apr; 103(14):5247-8. PubMed ID: 16567652
    [No Abstract]   [Full Text] [Related]  

  • 57. Renal response to prostaglandin E1 infusion in polycystic kidney disease versus non-polycystic renal disease.
    Uemasu J; Munemura C; Fujihara M; Kawasaki H
    Clin Nephrol; 1995 Oct; 44(4):225-30. PubMed ID: 8575121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biology of polycystic kidney disease.
    Carone FA; Bacallao R; Kanwar YS
    Lab Invest; 1994 Apr; 70(4):437-48. PubMed ID: 8176884
    [No Abstract]   [Full Text] [Related]  

  • 59. Cardiovascular manifestations of autosomal dominant polycystic kidney disease in young adults.
    Handa SP
    Clin Invest Med; 2006 Dec; 29(6):339-46. PubMed ID: 17330449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Planar cell polarity and polycystic kidney disease].
    Fischer E; Pontoglio M
    Med Sci (Paris); 2006; 22(6-7):576-8. PubMed ID: 16828030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.